Riopan (magaldrate) chewable tablets 800 mg. №20


Heartburn, acidic belching, feeling of heaviness and overflow in the stomach area.

Category: Manufacturer: Germany


Storage Riopan 
active substance: magaldrate;
1 chewable tablet contains 800 mg of anhydrous magaldrate;
Excipients: sorbitol (E 420), polyethylene glycol 4000, maltol, aromatic caramel, aromatic cream, calcium behenate.

Dosage form
Chewable tablets.

Pharmacological properties
Riopan is an antacid with a layered lattice structure. The active substance of Riopan is magaldrate. It contains aluminum and magnesium hydroxide in one molecule.
Riopan reduces the amount of acid in the stomach and, depending on the dose and pH level, binds pepsin, bile acids and lysolecithin. This eliminates the aggressive action of gastric juice and forms a layer that protects its mucous membrane.
Acid binding is due to the binding of protons by sulfate and hydroxide ions of the middle layer of the lattice. During neutralization, the lattice structure collapses.
800 mg of anhydrous magaldrate neutralizes approximately 18-25 mg-eq of hydrochloric acid.
The tablet of Riopan 800 mg corresponds in vitro to approximately 19 mg-eq of acid-neutralizing activity. Because the pH level is maintained in the range of 3 to 5 for 20-40 minutes, which is therapeutically optimal, the use of the drug does not cause acid rebound.
Magaldrate does not affect gastric motility.

Heartburn, sour belching, heaviness and fullness in the stomach.


  • Hypersensitivity to the active substance or to other components of the drug.
  • Hypophosphatemia.
  • Intrusion intolerance and sorbitol.
  • Habitual constipation.
  • Chronic diarrhea.
  • Severe abdominal pain of unspecified origin.
  • Alzheimer’s disease.

The drug can be used in patients with impaired renal function (creatinine clearance <30 ml / min) only with regular monitoring of plasma magnesium and aluminum levels. The level of aluminum in the blood plasma should not exceed 40 ng / ml.

Method of application and dosage
Adults: the recommended dose is 1 tablet of Riopan.
In case of minor complaints, the drug should be used 0.5–1 hour after a meal or immediately upon the appearance of significant complaints.
Chewable tablets should be swallowed or chewed thoroughly.
Do not exceed the maximum daily dose – 8 chewable tablets (6.4 g of magaldrate).
If the symptoms do not disappear after 2 weeks of treatment with the drug, you need to see a doctor for examination.
Elderly patients do not require dose adjustment.

Currently, there are no data from systematic studies on the use and safety of the drug in children.

No cases of overdose with Riopan have been reported.
Symptoms of an overdose of aluminum hydroxide and magnesium hydroxide are manifested by rapid fatigue, flushing, exhaustion, muscle weakness and inappropriate behavior.
There may also be signs of metabolic alkalosis: mood swings or mental activity, numbness or muscle pain, nervousness and fatigue, slow breathing, unpleasant taste sensations.
Treatment of magnesium overdose: rehydration, forced diuresis. You can prescribe calcium gluconate intravenously. In case of renal failure, hemodialysis or peritoneal dialysis is required.

Side effects:

  • From the digestive tract: diarrhea, constipation.
  • In patients with renal insufficiency or long-term use of high doses of the drug may increase levels of aluminum and magnesium in the blood, which can lead to the accumulation of aluminum, mainly in nervous and bone tissues, and to a deficiency of phosphates.
  • Disturbance of taste (feeling of taste of chalk); nausea; vomiting; aluminum and / or magnesium intoxication, most often in patients with renal insufficiency.
  • Dementia, deterioration in Alzheimer’s disease.
  • Osteomalacia, osteoporosis.
  • Hypersensitivity reactions, including pruritus, urticaria, angioneurotic edema and anaphylactic reactions, bronchospasm.
  • Reduction of phosphorus in the body is possible with the use of even the usual doses of the drug in patients whose diet is characterized by low phosphorus.
  • Enhancement of resorption processes in bone tissue, hypercalciuria.

In patients with renal insufficiency, prolonged use of high doses of aluminum and magnesium salts may lead to the development of encephalopathy, microcytic anemia or worsen the course of osteomalacia induced by dialysis. Prolonged use or intake of high doses can cause phosphorus deficiency syndrome (loss of appetite, muscle weakness, weight loss).
Aluminum hydroxide can be dangerous for patients with porphyria who are on hemodialysis.

Expiration date
3 years.
Do not use the drug after the expiration date indicated on the package.

Storage conditions
Store at a temperature not exceeding 25 ° C. Keep out of reach of children!